We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Telesis Bio Inc | NASDAQ:TBIO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0407 | -11.49% | 0.3135 | 0.31 | 0.44 | 0.3591 | 0.3162 | 0.3396 | 146,691 | 05:00:02 |
“In 2019, we have continued to make significant progress towards our goal of developing a new class of medicines utilizing our mRNA therapeutic platform. Building on the early positive data in our ongoing Phase 1/2 clinical trial in CF, we expanded our focus in pulmonary diseases and have also continued to build out critical operations across the Company including development of our delivery platform, growth of our manufacturing capabilities and preparations for future clinical development,” said Ronald Renaud, chief executive officer of Translate Bio. “In 2020, we look forward to sharing results from the multiple-ascending dose part of the Phase 1/2 CF clinical trial and continuing to advance our pipeline of mRNA therapeutics.”
Third Quarter 2019 and Recent Highlights
Anticipated Milestones
Upcoming Events
Third Quarter 2019 Financial Results and Financial Guidance
Translate Bio ended the third quarter of 2019 with $210.2 million in cash, cash equivalents and short-term investments and 60,020,725 shares of common stock outstanding, which includes gross proceeds of $90.0 million raised through a public offering of 9,000,000 shares of its common stock in September 2019. The Company expects that its existing cash, cash equivalents and investments will enable it to fund its operations into the first half of 2021.
Translate Bio reported a net loss of $21.2 million and $42.6 million for the three months ended September 30, 2019 and 2018, respectively.
Collaboration revenue was $1.3 million and $0.2 million in the three months ended September 30, 2019 and 2018, respectively, which was derived from the collaboration and license agreement that the Company entered into with Sanofi Pasteur in 2018.
Operating expenses for the three months ended September 30, 2019 were $22.9 million, compared to $45.7 million for the same period in 2018, and were comprised of the following:
About Translate BioTranslate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The Company’s MRT platform is designed to develop product candidates that deliver mRNA carrying instructions to produce intracellular, transmembrane and secreted proteins for therapeutic benefit. Translate Bio is primarily focused on applying its MRT platform to treat pulmonary diseases caused by insufficient protein production or where production of proteins can modify disease. The Company also believes its technology is applicable to a broad range of diseases, including diseases that affect the liver, eye and central nervous system. Additionally, the MRT platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as infectious disease and oncology. Translate Bio’s lead program is being developed as a treatment for cystic fibrosis (CF) and is in an ongoing Phase 1/2 clinical trial. For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.
Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the potential for MRT5005 to address the underlying cause of CF and benefit patients; Translate Bio’s plans to report data from the additional SAD dose group and MAD part of the Phase 1/2 clinical trial of MRT5005 in 2020; Translate Bio’s plans to advance its pipeline of mRNA therapeutics and validate targets for additional pulmonary diseases; the period in which Translate Bio expects that its existing cash, cash equivalents and investments will enable it to fund its operations; Translate Bio’s beliefs regarding the broad applicability of its MRT platform; and Translate Bio’s plans, strategies and prospects for its business, including its lead development programs. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forward”, “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from current expectations and beliefs, including but not limited to: Translate Bio’s ability to advance the development of its platform and programs under the timelines it projects, demonstrate the requisite safety and efficacy of its product candidates and replicate in clinical trials any positive findings from preclinical studies; the content and timing of decisions made by the U.S. Food and Drug Administration, other regulatory authorities and investigational review boards at clinical trial sites, including decisions as it relates to ongoing and planned clinical trials; Translate Bio’s ability to obtain, maintain and enforce necessary patent and other intellectual property protection; the availability of significant cash required to fund operations; competitive factors; general economic and market conditions and other important risk factors set forth under the caption “Risk Factors” in Translate Bio’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019 filed with the Securities and Exchange Commission on November 6, 2019 and in any other subsequent filings made by Translate Bio. Any forward-looking statements contained in this press release speak only as of the date hereof, and Translate Bio specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
TRANSLATE BIO, INC. | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(IN THOUSANDS) | ||||||||||||||||
(UNAUDITED) | ||||||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
2019 | 2018 | 2019 | 2018 | |||||||||||||
Collaboration revenue | $ | 1,266 | $ | 238 | $ | 3,914 | $ | 238 | ||||||||
Operating expenses: | ||||||||||||||||
Research and development | 17,295 | 12,933 | 51,343 | 40,854 | ||||||||||||
General and administrative | 6,881 | 5,957 | 21,284 | 16,726 | ||||||||||||
Change in fair value of contingent consideration | (19,834 | ) | 26,829 | (3,243 | ) | 39,589 | ||||||||||
Impairment of intangible asset | 18,559 | — | 18,559 | — | ||||||||||||
Total operating expenses | 22,901 | 45,719 | 87,943 | 97,169 | ||||||||||||
Loss from operations | (21,635 | ) | (45,481 | ) | (84,029 | ) | (96,931 | ) | ||||||||
Other income (expense): | ||||||||||||||||
Interest income | 428 | 318 | 1,306 | 499 | ||||||||||||
Other expense | (20 | ) | (7 | ) | (20 | ) | (52 | ) | ||||||||
Total other income (expense), net | 408 | 311 | 1,286 | 447 | ||||||||||||
Loss before benefit from income taxes | (21,227 | ) | (45,170 | ) | (82,743 | ) | (96,484 | ) | ||||||||
Benefit from income taxes | — | 2,524 | 486 | 5,126 | ||||||||||||
Net loss | $ | (21,227 | ) | $ | (42,646 | ) | $ | (82,257 | ) | $ | (91,358 | ) | ||||
TRANSLATE BIO, INC. | |||||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||||||
(IN THOUSANDS) | |||||||||||
(UNAUDITED) | |||||||||||
September 30, | December 31, | ||||||||||
2019 | 2018 | ||||||||||
Assets | |||||||||||
Current assets: | |||||||||||
Cash and cash equivalents | $ | 98,930 | $ | 55,199 | |||||||
Short-term investments | 111,233 | 88,904 | |||||||||
Prepaid expenses and other current assets | 6,648 | 4,474 | |||||||||
Restricted cash | 950 | 1,025 | |||||||||
Total current assets | 217,761 | 149,602 | |||||||||
Property and equipment, net | 10,680 | 10,245 | |||||||||
Right-of-use assets, net | 10,527 | — | |||||||||
Goodwill | 21,359 | 21,359 | |||||||||
Intangible assets, net | 86,695 | 106,445 | |||||||||
Other long-term assets | 2,492 | — | |||||||||
Total assets | $ | 349,514 | $ | 287,651 | |||||||
Liabilities and Stockholders' Equity | |||||||||||
Current liabilities: | |||||||||||
Accounts payable | $ | 3,407 | $ | 5,168 | |||||||
Accrued expenses | 8,767 | 6,547 | |||||||||
Current portion of deferred revenue | 12,603 | 2,572 | |||||||||
Current portion of operating lease liability | 489 | — | |||||||||
Total current liabilities | 25,266 | 14,287 | |||||||||
Long-term portion of contingent consideration | 100,399 | 103,642 | |||||||||
Deferred revenue, net of current portion | 30,046 | 41,841 | |||||||||
Deferred tax liabilities | — | 481 | |||||||||
Deferred rent | — | 2,105 | |||||||||
Operating lease liability, net of current portion | 12,230 | — | |||||||||
Total liabilities | 167,941 | 162,356 | |||||||||
Stockholders’ equity: | |||||||||||
Common stock | 60 | 45 | |||||||||
Additional paid-in capital | 509,294 | 371,257 | |||||||||
Accumulated deficit | (328,460 | ) | (246,203 | ) | |||||||
Accumulated other comprehensive income | 679 | 196 | |||||||||
Total stockholders' equity | 181,573 | 125,295 | |||||||||
Total liabilities and stockholders' equity | $ | 349,514 | $ | 287,651 | |||||||
Contacts for Translate Bio
Investors MediaTeri Dahlman Maura Gavaghantdahlman@translate.bio mgavaghan@translate.bio857-242-7792 857-242-7789
1 Year Telesis Bio Chart |
1 Month Telesis Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions